Tag: Clots
ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
Risk for patients in rivaroxaban group reduced during the on-treatment period
Recommended Therapies for Polycythemia Vera Underused
Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients
Clinical Decision Support System Ups Outpatient PE Management
Home discharge rate increased at intervention sites; no increase in return visits, adverse outcomes
Patient Education Ups VTE Prophylaxis in Hospital Setting
Targeted patient-centered intervention reduces nonadministration of pharmacologic prophylaxis
Diagnostic Strategy Can Rule Out PE in Pregnant Women
Strategy includes clinical probability assessment, D-dimer, lower-limb compression ultrasound, CTPA
Aspirin, Anticoagulants Similarly Prevent VTE After TKA
In patients having total knee arthroplasty, aspirin non-inferior for venous thromboembolism, death
Risk of Venous Thromboembolism Recurrence High
At 6 months, rates for provoked, unprovoked, cancer-related VTE are 6.8, 6.92, 9.06 per 100 person-years
No Clear Benefit for Rivaroxaban After Hospital Discharge
Incidence of major bleeding low with rivaroxaban, but clot risk not lower
Transfeminine Persons Have Increased VTE Incidence
More pronounced differences in VTE, ischemic stroke for those who initiated hormone tx during follow-up
VTE Linked to Acute Decline in Physical Function in Women
Greater difference in physical decline for women specifically reporting pulmonary embolism
